Six reasons to enhance your sinus action plan
PROPEL™ implants are clinically proven to maintain patency and improve patient outcomes by reducing inflammation in the post-operative healing period.
Individualized treatment options 1-3
- ENT offers a family of 3 steroid-eluting implants under one brand: PROPEL™
- PROPEL™ implants promote a tailored approach to postoperative care with options on implants’ indication, size, shape, and delivery system
- The PROPEL™ implant provides localized corticosteroid delivery, minimizing the reliance of patient compliance4
Watch Prof. Hesham Saleh, Prof. Jan Gosepath and Dr. David Conley discuss the benefits of using PROPEL™ following surgeries.
PROPELTM family of sinus implants
The PROPEL™ family of implants offers 3 steroid-eluting implants under one brand, allowing ENT surgeons to select the best option that conforms to the anatomical needs of their patients1-3
References
1
PROPEL™ [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013.
2
PROPEL™ Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
3
PROPEL™ Contour [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
4
Han JK, Marple BF, Smith TL, et al. Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis. Int Forum Allergy Rhinol. 2012;2(4):271-279.
5
Data on file, Intersect ENT, Inc. Calculated Patients-PROPEL™ Family. Q2 2019.
6
Li PM, Downie D, Hwang PH. Controlled steroid delivery via bioabsorbable stent: safety and performance in a rabbit model. Am J Rhinol Allergy. 2009;23(6):591-596.
UC202311001EE MPM – 12525 Rev. 1.0
CRS, chronic rhinosinusitis; MF.
See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at cema.medtronic.com.
PROPEL™ Important Safety Information:
The PROPEL™ sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL™ for the ethmoid sinus, PROPEL™ Mini for the ethmoid sinus/frontal sinus opening, and PROPEL™ Contour for the frontal sinus ostia in chronic rhinosinusitis patients. Contraindications include patients with intolerance to MF or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.intersectENT.co.uk. For use by healthcare professionals only.
Important Reminder: This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.
PROPEL™ and PROPEL™ Mini:
PROPEL™ Contour:
